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Among the three human apolipoprotein E (apoE) isoforms, apoE4 increases the risk of Alzheimer’s disease
(AD). While transporting cholesterol is a primary function, apoE also regulates amyloid-b (Ab) metabolism,
aggregation, and deposition. Although earlier work suggests that different affinities of apoE isoforms to
Ab might account for their effects on Ab clearance, recent studies indicate that apoE also competes with
Ab for cellular uptake through apoE receptors. Thus, several factors probably determine the variable effects
apoE has on Ab. In this Review, we examine biochemical, structural, and functional studies and propose
testable models that address the complex mechanisms underlying apoE-Ab interaction and how apoE4
may increase AD risk and also serve as a target pathway for therapy.Introduction
Alzheimer’s disease (AD) is the most common form of late-life
mental failure in humans, which accounts for an estimated
60%–80% of dementia cases (Thies and Bleiler, 2013). Senile
plaques and intracellular neurofibrillary tangles are hallmarks of
AD pathology. The generation of amyloid-b (Ab) peptides of
either 40 or 42 amino acids in length, from amyloid precursor
protein (APP), and their subsequent accumulation, aggregation,
and deposition in brain parenchyma, as senile plaques, and in
perivascular regions, as cerebral amyloid angiopathy (CAA),
are central and perhaps defining events in the pathogenesis of
AD (Hardy and Selkoe, 2002). In addition to Ab deposits, soluble
Ab oligomers are shown to injure synapses by disrupting normal
synaptic functions and triggering downstream toxic pathways
leading to eventual neurodegeneration and cognitive deficits
(Mucke and Selkoe, 2012). Thus, the ‘‘amyloid cascade hypoth-
esis’’ is strongly supported by evidence of Ab-related pathology
early in the disease process and the specific roles of different
forms of Ab in neurotoxicity.
Less than 1% of AD cases are caused by dominantly inherited
genetic mutations in genes including APP, PSEN1, and PSEN2
(Thies and Bleiler, 2013). Inheriting any of these genetic muta-
tions accelerates Ab production, resulting in the development
of AD usually before the age of 60, which is commonly referred
to as early-onset familial AD (FAD). Late-onset AD (LOAD),
or the sporadic occurrence of the disease later in life, represents
the majority of AD cases (Hardy and Selkoe, 2002). In LOAD, the
disturbance of Ab clearance machinery appears to be a leading
cause of Ab accumulation in the brain (Mawuenyega et al., 2010).
Indisputable evidence showing the ε4 allele of the APOE gene,
which encodes a lipid/cholesterol carrier apolipoprotein E
(apoE), is a stronger genetic risk factor for AD than the more
common ε3 allele, whereas the presence of the ε2 allele is pro-
tective (Bu, 2009; Liu et al., 2013). The presence of the ε4 allele
of the APOE gene not only dose dependently increases the
risk for AD but also lowers the age of onset (Bu, 2009; Corder740 Neuron 81, February 19, 2014 ª2014 Elsevier Inc.et al., 1993; Liu et al., 2013). ApoE4 contributes to the pathogen-
esis of AD probably by both loss-of-function in neuroprotection
and gain-of-function in neurotoxicity compared to apoE3 (Bu,
2009; Huang and Mucke, 2012). Although several pathways
underlying the risk associated with apoE4-linked AD have been
defined through in vitro and in vivo studies, the exact mecha-
nisms are still not completely understood and those that have
been proposed remain controversial. Nonetheless, the differen-
tial effects of apoE isoforms on amyloid pathology and Ab
metabolism have been confirmed in humans, animal models,
and cellular studies. In this Review, we will discuss how apoE
isoforms differentially regulate AD pathogenic pathways with
particular focus on Ab-dependent pathways.
Back to Basics: Biochemical and Structural Features of
apoE
ApoE is a glycoprotein of 299 amino acids with amolecular mass
of 34 kDa. It was originally identified as an apolipoprotein en-
riched on cholesterol- and triglyceride-rich plasma lipoproteins
synthesized by the liver in humans and animals (Mahley, 1988;
Mahley and Rall, 2000). ApoE mediates the transport and deliv-
ery of cholesterol and other lipids through cell surface apoE
receptors (Mahley, 1988; Mahley and Rall, 2000). The mRNA
profile has shown that the liver is the major tissue in which
apoE is synthesized, accounting for >75% of total apoE, fol-
lowed by the brain (Elshourbagy et al., 1985). The concentrations
of apoE in plasma and cerebrospinal fluid (CSF) are estimated to
be 40–70 mg/ml and 3–5 mg/ml, respectively (Mahley et al.,
2009; Pitas et al., 1987b). ApoE reporter mice with EGFP inser-
tion into the Apoe gene locus exhibit highly expressed apoE in
hepatocytes and peritoneal macrophages. In the brain, astro-
cytes, microglia, vascular smooth muscle cells, and choroid
plexus constitutively express apoE, whereas neurons predomi-
nantly synthesize apoE under stress conditions (Xu et al.,
2006). The multiple isoforms of human apoE were first identified
when human apoE polymorphisms were characterized using
Figure 1. Schematic Illustration of Structural
and Functional Regions of apoE and Ab
Human apoE is a glycosylated protein of 299
amino acids consisting of a receptor-binding re-
gion (residues 136–150) in the N-terminal domain
(residues 1–167) and a lipid-binding region (resi-
dues 244–272) in the C-terminal domain (residues
206–299) (Chen et al., 2011). ApoE also has two
heparin-binding sites, each within the N-terminal
and the C-terminal domains (Ji et al., 1993; Saito
et al., 2003). The residues that distinguish the
apoE isoforms are located at residues 112 and
158, where apoE2 has Cys residues at both po-
sitions, apoE3 has a Cys residue at 112 and an Arg
residue at 158, and apoE4 has Arg residues at
both positions (Rall et al., 1982; Weisgraber et al.,
1981). The domain interaction between Arg 61
and Glu 255 in apoE4 is also indicated (Mahley
and Rall, 2000; Mahley et al., 2009; Wilson et al.,
1991), although other structural studies have not
confirmed this (Chen et al., 2011). Ab can interact
with both the receptor-binding region and lipid-
binding region of apoE, as well as with heparin
through its residues 13–17 (Strittmatter et al.,
1993; Winkler et al., 1999).
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familial lipoprotein disorder type III hyperlipoproteinemia (Ute-
rmann et al., 1977). Because of their different charges, human
apoE has mainly three patterns of band designated with each
isoelectric point as E2 (pH 5.4), E3 (pH 5.55), and E4 (pH 6.1)
(Mahley and Rall, 2000; Utermann et al., 1977). The heterogene-
ity of major isoforms apoE2, apoE3, and apoE4 is due to genetic
polymorphisms (Zannis and Breslow, 1981). Complete amino
acid sequencing revealed that apoE2 has Cys residues at posi-
tions 112 and 158, apoE3 has a Cys residue at 112 and an Arg
residue at 158, and apoE4 has Arg residues at both positions
(Rall et al., 1982; Weisgraber et al., 1981) (Figure 1). These differ-
ences at amino acid residues 112 and 158 among apoE isoforms
probably induce significant, perhaps profound, changes in their
structures and associated biological functions. The minor iso-
forms result from variable posttranslational O-linked glycosyla-
tion/sialylation of major apoE isoforms at Thr 194, resulting in
further negative charges (Figure 1) (Wernette-Hammond et al.,
1989; Zannis and Breslow, 1981). Posttranslational modification
and subsequent deglycosylation of apoE probably lead to its
heterogeneous sialylation. Although newly secreted apoE is
highly sialylated (Wernette-Hammond et al., 1989), 80%–85%
of human plasma apoE is in the asialo form, with monosialo
and disialo isoforms as the minor species (Zannis and Breslow,
1981). Interestingly, apoE in the brain has higher sialylation
than that in plasma (Pitas et al., 1987a). Further studies are
needed to understand how glycosylation of apoE affects its
metabolism and functions in an isoform-dependent and/or tis-
sue-dependent manner.
The nuclear magnetic resonance (NMR) of a monomeric
mutant form of apoE3, which has mutations in the C-terminal
domain to prevent aggregation, revealed for the first time the
full-length structure of apoE in which the N-terminal domain (res-
idues 1–167) and C-terminal domain (residues 206–299) are
separated by a hinge region (residues 168–205) (Chen et al.,2011). The N-terminal domain contains a four-helix bundle,
which was detected by both X-ray crystallography (Wilson
et al., 1991) and NMR (Sivashanmugam and Wang, 2009). In
monomeric mutant apoE3, Arg 61 forms a hydrogen bond with
Thr 194 and Glu 255, forming a salt bridge with Lys 95 (Chen
et al., 2011). In contrast to this, X-ray crystallographic analyses
of the N-terminal domain structure of apoE revealed that Arg
112 forms a salt bridge with Glu 109, resulting in the exposure
of Arg 61 away from the four-helix bundle in apoE4, whereas
this side chain in apoE3 is buried (Dong et al., 1994). As a result,
Arg 61 in apoE4 is predicted to interact with Glu 255, leading to
interactions between the N- and C-terminal domains (Mahley
and Rall, 2000; Mahley et al., 2009; Wilson et al., 1991). Fluores-
cence resonance energy transfer (FRET) and electron paramag-
netic resonance (EPR) revealed that the distance between Arg 61
and Glu 255 is closer in both lipid-free and phospholipid-bound
apoE4 than in apoE3 (Hatters et al., 2005). This domain-domain
interaction was also observed in apoE4-expression neuronal
cells by live cell imaging (Xu et al., 2004). Although the NMR
structure does not support the domain-domain interaction in
apoE4, it is likely that the single amino acid difference at position
112 between apoE3 (Cys) and apoE4 (Arg) has an influence on its
structure. Future technology that allows for determination of full-
length wild-type apoE3 and apoE4, either in lipid-free or lipid-
bound state, should teach us how a single amino acid difference
can have a profound impact on structure and functions, in partic-
ular those related to AD pathways.
The major functional regions of apoE are the receptor-binding
site (residues 136–150) in the N-terminal domain and the lipid-
binding site (residues 244–272) in the C-terminal domain
(Figure 1) (Hatters et al., 2006a). NMR analysis of apoE3 demon-
strated that several hydrophilic residues in the C-terminal
domain are buried within the domain interface. The exposed hy-
drophobic residues destabilize the C-terminal domain and form
a large exposed hydrophobic surface to attract lipids for initialNeuron 81, February 19, 2014 ª2014 Elsevier Inc. 741
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ence for high-density lipoproteins (HDL), whereas apoE4 is
frequently associated with very low-density lipoproteins (VLDL)
and low-density lipoproteins (LDL) (Dong et al., 1994; Hatters
et al., 2006a). In apoE4, replacement of Arg 61 with Thr, or Glu
255 with Ala, leads to apoE3-like HDL preference (Dong et al.,
1994; Hatters et al., 2006a). Therefore, Arg 61, Glu 255, or their
interaction is probably necessary for VLDL preference in
apoE4. One consequence of different lipoprotein preference by
apoE4 is the increased plasma cholesterol levels, which in turn
increases the risk for cardiovascular diseases, in particular
atherosclerosis (Davignon et al., 1988).
Major apoE receptors belong to the LDL receptor (LDLR) fam-
ily, including LDLR (Innerarity and Mahley, 1978), LDLR-related
protein 1 (LRP1) (Beisiegel et al., 1989; Kowal et al., 1989),
VLDL receptor (VLDLR), and apoE receptor 2 (apoER2) (Kim
et al., 1996). LDLR interacts with both apoB-LDL and apoE-
HDL particles (Innerarity et al., 1979); however, apoE-HDL parti-
cles have a 10- to 100-fold higher binding affinity to the cell
surface receptor than the apoB-LDL particles (Innerarity and
Mahley, 1978). LRP1 recognizes more than 30 structurally and
functionally distinct ligands, including apoE, a2-macroglobulin,
tissue-type plasminogen activator, APP, and Ab (Herz and
Strickland, 2001). Although both LRP1 and LDLR are major
apoEmetabolic receptors, they differ in ligand recognition. While
LRP1 prefers apoE-enriched particles or apoE aggregates,
LDLR binds naturally secreted or circulating apoE particles
(Bu, 2009). Thus, the receptor-binding specificity of apoE is influ-
enced by its lipidation state and the density of apoE epitopes.
For binding to LDLR, the positively charged residues within the
N-terminal receptor-binding region of apoE are probably buried
in a lipid-free state but are exposed upon lipidation (Chen et al.,
2011). LRP1 binding, which appears to require either apoE
enrichment or aggregation, is less understood but may require
simultaneous exposure of multiple receptor-binding epitopes.
In addition to the LDLR family, apoE also binds to cell surface
heparan sulfate proteoglycans (HSPGs) (Ji et al., 1993), either
in lipid-free or lipidated forms (Saito et al., 2003), through both
the receptor-binding region in the N-terminal domain and the
basic residues around Lys 233 in the C-terminal domain (Saito
et al., 2003) (Figure 1). The C-terminal domain of recombinant
apoE protein displays a stronger affinity and faster kinetics in
terms of binding to heparin. Thus, HSPG binding through basic
residues around Lys 233 is likely to be the first step, whichmakes
the receptor-binding region in N-terminal domain available for
the second step of HSPG binding (Futamura et al., 2005).
Furthermore, LRP1 can form a complex with HSPG (Ji et al.,
1993). In theHSPG/LRP1 uptake pathway, either apoE first binds
to HSPG and is then transferred to LRP1 for subsequent uptake,
or it can bind directly to the HSPG/LRP1 complex (Ji et al., 1993).
The receptor-binding function of apoE has been shown to be iso-
form dependent. While apoE3 and apoE4 bind with similar affin-
ity to LDLR, apoE2 has less binding affinity (Schneider et al.,
1981). The unique Cys 158 in apoE2 eliminates a salt bridge be-
tween Arg 158 and Asp 154 with the formation of a new salt
bridge between Arg 150 and Asp 154, thus reducing its affinity
to the LDLR (Dong et al., 1994). Due to this reduced binding of
apoE2 to LDLR, apoE2 homozygous individuals are at higher742 Neuron 81, February 19, 2014 ª2014 Elsevier Inc.risk for a genetic disorder termed type III hyperlipoproteinemia,
which is characterized by increased plasma levels of cholesterol
and triglycerides (Hatters et al., 2006a). The reduced affinity of
apoE2 to LRP1 compared to apoE3 and apoE4 appears to be
less severe (Kowal et al., 1990) and there seem to be no major
differences among the apoE isoforms in their ability to bind to
HSPG (Mahley and Rall, 2000).
Although we still do not know the full-length structures of wild-
type apoE due to its highly aggregative nature, numerous
biochemical, structural, and functional studies in lipid transport
have provided important clues as to why subtle changes in
sequence among the three apoE isoforms can generate suffi-
cient differences in risk for cardiovascular diseases and AD. As
we further explore the mechanisms of apoE isoforms in AD path-
ogenesis, in particular those related to Ab pathways, it is impor-
tant to consider all available knowledge, some of which was
generated decades ago (Mahley, 1988), as we design further
studies to advance our understanding of apoE physiological
and pathophysiological functions.
ApoE and Alzheimer’s Disease: Amyloid Is the Clue
In humans, theAPOE gene exists as three polymorphic alleles (ε2,
ε3, and ε4), with theAPOE ε3 allele being themost common (77%)
and ε2 allele the least common (8%) (Mahley, 1988). Much evi-
dence has confirmed thatAPOE4 is the strongest genetic risk fac-
tor for AD (Harold et al., 2009; Lambert et al., 2009), as APOE4
significantly increases the risk for both early-onset AD and late-
onset AD (Chartier-Harlin et al., 1994; Houlden et al., 1998). The
ε4 allele frequency is estimated to be about 15% in the general
population but is40% inADpatients (Farrer et al., 1997). In addi-
tion to increasing theprevalenceofAD, thepresenceof theAPOE4
allele also lowers the age of onset for AD in a gene dose-depen-
dent manner (Corder et al., 1993; Farrer et al., 1997). Among ε4
homozygotes, the frequency of AD andmean age at clinical onset
are 91%and 68 years of age, respectively, compared to 47% and
76 years of age in ε4 heterozygotes and 20% and 84 years in ε4
noncarriers (Corder et al., 1993). Importantly, Ab deposition as
senile plaques is more abundant in APOE4 carriers compared
with noncarriers (Kok et al., 2009; Polvikoski et al., 1995), and
APOE4 increases Ab deposition in the brains of elderly subjects
with normal cognitive function, although the association is weaker
than that in AD patients (Reiman et al., 2009).
A large-scale study of CSF samples from both normal individ-
uals and AD patients demonstrated that apoE protein levels in
CSF positively associated with CSF Ab42 levels independent
of APOE4 genotype, although there was no significant difference
in CSF apoE levels between AD patients and normal individuals
(Cruchaga et al., 2012). Because there is a strong correlation be-
tween low CSF Ab42 and high Ab brain deposition detected by
Pittsburgh compound B (PiB)-positron emission tomography
(PET) imaging, lower CSF apoE levels in effect correlate with
increased Ab deposition in the brain (Fagan et al., 2006). Thus,
CSF apoE protein levels appear to hold potential as an endophe-
notype marker for AD pathology. Interestingly, CSF and plasma
apoE protein levels are reduced in APOE4 carriers (Cruchaga
et al., 2012). As there was no association between apoE geno-
type and apoE mRNA levels (Cruchaga et al., 2012), the effect
of apoE isoforms on CSF apoE levels is likely due to the different
Neuron
Reviewconformational stability that affects their proteolysis. The apoE
isoforms differ in the stability of their N-terminal domains with
apoE4 being the least resistant to thermal and chemical denatur-
ation, apoE2 the most, and apoE3 showing intermediate resis-
tance (Hatters et al., 2006a). These studies suggest that reduced
apoE levels in APOE4 carriers and in AD patients can facilitate
the accumulation of Ab in the brain. Supporting this, when Ab
and apoE levels were analyzed in multiple brain areas of nonde-
mented individuals, apoE levels negatively correlated with Ab
levels both in APOE4 carriers and noncarriers, indicating that
apoE affects region-specific Ab levels by preventing Ab accumu-
lation (Shinohara et al., 2013). Taken together, these clinical
studies using human samples suggest that apoE isoforms
impact AD pathogenesis by driving Ab pathology. The following
sections in this Review discuss preclinical studies highlighting
potential pathways by which apoE isoforms affect Ab meta-
bolism and aggregation.
ApoE/Ab Complexes: How We Assess Them Makes a
World of Difference
Histological analysesofADbrains reveal that apoE iscodeposited
withAb in amyloidplaques (Nambaet al., 1991), indicatingadirect
association between apoE and Ab in AD pathogenesis. Several
in vitro studies have shown that synthetic Ab peptides can bind
to apoE either secreted from cells (LaDu et al., 1994) or purified
fromhumanCSF (Wisniewski et al., 1993) andplasma (Strittmatter
et al., 1993).Human recombinantapoEbinds to immobilizedAb40
with a high affinity (KD = 20 nM). Its interaction is greatly influ-
enced by the conformational state of Ab, in which apoE shows
stronger preference for Ab peptides with higher b sheet structure
(Golabek et al., 1996). Epitopemapping reveals that residues 13–
17 in Ab and residues 144–148 in the apoE N-terminal region, as
part of the receptor-binding domain (Winkler et al., 1999), are
common sites that interact with each other. In addition, residues
244–272 in the apoE C-terminal region also appear to be critical
for the formation of apoE/Ab complexes (Strittmatter et al.,
1993). Interestingly, heparin interacts with both Ab-binding sites
in apoE and an apoE-binding site in Ab (Figure 1) (Brunden
et al., 1993; Saito et al., 2003). Thus, the heparin-binding motifs
in both apoE and Ab are critical for their interaction. HSPG is a
major cell surface receptor for both apoE and Ab; thus, improved
understanding of the interactions between apoE, Ab, and cell
surface HSPG, as discussed later, should provide further clues
as to how these interactions influence AD pathogenesis.
The notion that an Ab-binding site overlaps with the lipid-bind-
ing region within the apoE C-terminal domain suggests that Ab
and lipids might compete with one another for apoE binding
(Figure 1). In the brain, apoE is mainly secreted by astrocytes,
where a plasma membrane ATP-binding cassette transporter
A1 (ABCA1) loads cholesterol and other lipids onto lipoprotein
particles (Koldamova et al., 2010). Astrocyte-secreted apoE par-
ticles are small and have different lipid components compared
with apoE particles in CSF (LaDu et al., 1998), indicating that
newly synthesized apoE particles probably undergo modifica-
tions before they are transferred to neurons. Indeed, in vitro ex-
periments have shown that lipid-free recombinant apoE interacts
with immobilized Abwith a higher affinity than lipidated recombi-
nant apoE particles (Verghese et al., 2013), although conflictingresults have also been reported (Tokuda et al., 2000). Since Ab
can interact with both the lipid-binding site and the receptor-
binding site within apoE, the lipidation condition of apoE may
dictate both Ab-binding affinity and the binding site. Further, it
has been reported that incubation of recombinant apoE with
Ab oligomers severely impairs its lipid-binding ability (Tama-
mizu-Kato et al., 2008), suggesting that Ab oligomers can impair
the physiological function of apoE. As such ability of apoE to
transport lipids to neurons is critical for synaptic maintenance
and repair (Mahley and Rall, 2000), Ab oligomer-mediated distur-
bance of lipid binding in AD brains may further compromise syn-
aptic integrity and function.
The interaction between apoE and Ab appears to depend on
the specific apoE isoform being studied, its lipidation status,
and the cellular compartment generating it. The methods of
choice for evaluating apoE/Ab complexes may also influence
the results. For example, initial studies using purified and delipi-
dated apoE suggest that apoE4 binds to Ab with faster kinetics
than apoE3 when detected by western blotting, and such an
interaction is sensitive to both reducing agents and pH (Stritt-
matter et al., 1993). Subsequent studies using both HEK293
cell-secreted and native plasma apoE particles produced oppo-
site results, with apoE3 forming more abundant SDS-stable
complexes with Ab than apoE4 (LaDu et al., 1994, 1995). By
directly comparing purified, delipidated apoE with native apoE,
it was shown that apoE purification, which delipidates apoE,
changes the behaviors of apoE such that purification itself atten-
uates isoform-specific binding to Ab (LaDu et al., 1995). Using
EPR to assess apoE binding to Ab oligomers in solution and sur-
face plasmon resonance (SPR) on solid phase, Petrlova et al.
also detected stronger interactions for apoE3 than apoE4 (Pet-
rlova et al., 2011), further supporting the notion that apoE3 might
be more proficient in carrying Ab for cellular clearance and/or
preventing Ab from aggregation or neurotoxicity.
Our recent collaborative study led by the LaDu group has
shown that apoE4/Ab complexes are less stable than those
formed with apoE2 and apoE3 (Tai et al., 2013). Using a novel
ELISA quantifying apoE/Ab complexes, it was shown that
despite similar amounts of apoE/Ab complexes formed between
Ab and apoE2, apoE3, and apoE4, apoE4/Ab complexes are less
stable in the presence of a denaturing agent or lower pH. Inter-
estingly, the amounts of apoE/Ab complexes are fewer in
APOE4 carriers and in CSF from AD patients, which also have
higher levels of Ab oligomers. These results indicate the apoE
isoform-dependent function of apoE/Ab complexes and suggest
that the amounts of both apoE/Ab complexes and Ab oligomers
can serve as potential biomarkers for AD. One possible
mechanism responsible for the less stable nature of apoE4/Ab
complexes is the poorer lipidation status of apoE4 lipoprotein
particles. However, the pathophysiological factors that influence
the stability of apoE/Ab complexes and how Ab binding to apoE
impacts both the amounts and toxic functions of Ab oligomers
require further investigation.
Despite abundant evidence that apoE exhibits isoform-spe-
cific binding to Ab and that apoE/Ab complexes might modulate
Ab metabolism, the significance of apoE/Ab complexes was
called into question by a recent study led by the Holtzman group
(Verghese et al., 2013). In this study, when astrocyte-secreted orNeuron 81, February 19, 2014 ª2014 Elsevier Inc. 743
Figure 2. Ab Aggregation: Role of apoE
During the Ab aggregation process, Ab monomers
change their conformation to a b sheet-rich struc-
ture and form soluble oligomers or insoluble inter-
mediate aggregates. Such nuclei further accelerate
the fibrillogenesis to form large insoluble fibrils as
‘‘seeds’’ (Harper and Lansbury, 1997). The associ-
ation of apoE with an Ab nucleus is likely to block its
seeding effect, which accelerates Ab fibrillogenesis.
Under certain conditions, apoE and Ab may form
large coaggregates. Newly generated Ab fibrils can
bind to existing aggregates, resulting in the forma-
tion of even larger coaggregates, with or without
additional apoE (Wood et al., 1996a). Finally, these
aggregates may deposit as amyloid plaques in the
brain.
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derived Ab using concentrations resembling physiological con-
ditions, i.e., apoE:Ab ratio at 50–150:1 (Hesse et al., 2000;Wahrle
et al., 2007), the authors detected minimal amounts of apoE/Ab
complexes, accounting for 5% of total Ab (Verghese et al.,
2013). Interestingly, in astrocytes, apoE particles compete
with, rather than facilitate, cellular Ab uptake. These results
further highlight the importance of the source of apoE and Ab,
as well as experimental conditions, in addressing the roles of
apoE/Ab complexes in AD-related pathways. It is important to
note that despite significantly higher concentrations of apoE
than Ab in CSF, the exact concentrations of these molecules in
brain parenchyma, in particular around the synapses where
Ab is probably produced and exhibits neurotoxicity, is unclear.
Future studies should focus on developing technology, for
example, real-time in vivo microdialysis, to assess apoE-Ab
interactions and how a perturbation of their interaction affects
Ab metabolism, oligomerization, and toxicity.
ApoE and Ab Aggregation: ApoE Is Needed to Seed
Amyloid
Several in vivo studies have clearly shown that apoE is essential
for Ab deposition in APP transgenic amyloid model mice. When
Apoe knockout (KO) mice were crossed with amyloid model
PDAPP or Tg2576mice, Ab deposition in the form of amyloid pla-
ques and cerebral amyloid angiopathy (CAA) was dramatically
reduced (Bales et al., 1997; Irizarry et al., 2000). In particular,
although there is still significant, sometimes increased, Ab depo-
sition asdiffusedplaques, thioflavin S-positive fibril plaqueswere
virtually absent. These results clearly demonstrate the essential
role of mouse apoE in Ab fibrillogenesis, stabilization of fibrillar
Ab, and/or maturation of amyloid plaques (Bales et al., 1997;
Irizarry et al., 2000). However, the effects of apoE on Ab fibrillo-744 Neuron 81, February 19, 2014 ª2014 Elsevier Inc.genesis appear to depend on the origin of
apoE. In this respect, it is interesting to
note that expression of human apoE3 and
apoE4by astrocytes in theApoe-KOback-
ground decreased early Ab deposition
in PDAPP mice (Holtzman et al., 1999).
Human apoE-targeted replacement (TR)
mice, in which the mouse Apoe gene was
replaced with those encoding humanapoE isoforms, had less Ab deposition in the background of
Tg2576 mice compared with the control mice expressing mouse
apoE (Fryer et al., 2005b). Thus, human apoE isoforms probably
determine the amounts, morphology, localization, and fibrillo-
genesis of Ab deposits depending on whether mouse apoE is
present or not.
During the Ab aggregation process, soluble Ab peptides are
known to change their conformation into a b sheet structure
and form nucleuses (lag phase), which further accelerates the
process of fibrillogenesis to form insoluble fibrils with enriched
b sheet structures as ‘‘seed’’ (elongation phase) (Harper and
Lansbury, 1997). There are numerous studies analyzing the ef-
fects of apoE on Ab aggregation in vitro. However, the conclu-
sions are somewhat controversial as to whether apoE facilitates
or inhibitsAbaggregation. It hasbeenshown that highconcentra-
tions of apoE form high molecular weight coaggregates with Ab
(Chan et al., 1996), where apoE4 is likely to promote Ab aggrega-
tion more than apoE3 (Castano et al., 1995; Ma et al., 1994).
Moreover, it was shown that apoE increases the level of Ab olig-
omers in an isoform-dependent manner (apoE4 > apoE3 >
apoE2) (Hashimoto et al., 2012). Furthermore, apoE4 stabilizes
Ab oligomers more than apoE3 (Cerf et al., 2011). These findings
imply that apoE4 harmfully accelerates Ab aggregation in AD.
In contrast, other studies have reported that apoE decreases
Ab fibrillogenesis. ApoE strongly inhibits the initiation of Ab fibril
formation, when analyzed either with or without the addition of
preformed Ab aggregates as seeds (Naiki et al., 1997; Wood
et al., 1996b). Because apoE prefers to interact with Ab peptides
that are in b sheet structure (Golabek et al., 1996), apoE probably
captures Ab nuclei and prevents its seeding effects (Figure 2)
(Wood et al., 1996a). ApoE3 appears to interact with Ab more
than apoE4 as described; therefore, it is possible that apoE4 is
less effective in the inhibition of Ab fibril formation. In this case,
Figure 3. Cell Surface Binding and Endocytic
Trafficking of apoE and Ab
ApoE probably binds to Ab in an isoform-depen-
dent manner with apoE3 forming more stable apoE/
Ab complexes than apoE4 (LaDu et al., 1994, 1995).
LRP1, LDLR, and HSPG are major cell surface re-
ceptors that bind apoE, Ab, and apoE/Ab com-
plexes. In addition to forming a stable complex with
Ab (1), apoE probably competes with Ab to com-
mon cell surface receptors (2) (Verghese et al.,
2013). Endocytosed apoE either dissociates from
lipid components within the early endosomes due
to lower pH (3) and recycles (4) or is transported to
lysosomes for degradation (5). Endocytosed Ab is
typically delivered to lysosomes for degradation (5),
although a small amount of Ab can be recycled (4)
(Li et al., 2012). In some conditions, apoE and Ab
may be transferred through exosomes from the late
endosomes/multivesicular body (6). When Ab
accumulation overwhelms the capacity of lyso-
somes for degradation, the low pH in the lysosomes
provides a suitable environment to initiate Ab ag-
gregation (7) (Hu et al., 2009), which could injure
lysosomes and also provide seeding for further Ab
aggregation.
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apoE in preventing Ab fibrillation in AD. If the amount of apoE/Ab
complex increases as the soleproduct of the reaction, itmay form
large coaggregates (Figure 2) (Wood et al., 1996a). ApoE is also
known toaggregatewith irregular protofilament-likemorphology,
where the aggregates form at substantially different rates
depending on the isoform (apoE4 > apoE3 > apoE2) (Hatters
et al., 2006b). Thus, apoE4 may be able to produce more coag-
gregateswithAb through its self-aggregatingpropensity.Consis-
tentwith these findings, in vivo experiments have also shown that
apoE4-TR mice had more Ab deposition than apoE3-TR mice in
the background of amyloid model mice (Bales et al., 2009; Fryer
et al., 2005b). In yet a more aggressive amyloid model mice
referred to as 5xFAD (Oakley et al., 2006), amyloid plaque depo-
sitionwas in general greater in E4FADmice; E2/E3FADmice have
significantly more diffuse plaques with E4FAD exhibiting more
compact plaques (Youmans et al., 2012). Collectively, these
studies indicate that compared to apoE2 or apoE3, apoE4 is
either more likely to promote Ab fibrillogenesis or less effective
in preventing Ab aggregation, or both. Again, the specific out-
comes can be influenced by apoE isoform, lipidation status, ag-
gregation states, and the time and location of its presence during
the disease process. Further studies, perhaps by time-lapsed
recording in living mice with exogenously introduced apoE iso-
formswithdifferent lipidation statuses,might allowus togenerate
a clearer picture regarding the specific effects of apoE on Ab and
deposition. The effects of diffuse and fibrillar plaques on synaptic
functions and behaviors, in the presence of different apoE iso-
forms, also warrant further investigation.
ApoE and Ab in Endocytic Trafficking: Common
Receptors and Trafficking to Lysosomes
The major apoE receptors, LDLR, LRP1, and HSPG, are abun-
dantly expressed in the brain. These receptors mediate cellularuptake of Ab as well as apoE (Figure 3). The mRNAs of LDLR
and LRP1 are detected in several types of brain cells including
neurons, astrocytes, microglia, and oligodendrocytes (Fan
et al., 2001). While LDLR deficiency in mice leads to apoE accu-
mulation in the brain (Fryer et al., 2005a), overexpression of
LDLR decreases apoE levels by 50%–90% (Kim et al., 2009),
demonstrating the important role of LDLR in brain catabolism
of apoE. Since apoE2 has a lower affinity to the LDLR (Dong
et al., 1994), apoE2 catabolism is probably slower compared
to apoE3 or apoE4. Consistent with this notion, apoE levels in
CSF and plasma are higher than those of apoE3 or apoE4 both
in human (Cruchaga et al., 2012) and in apoE-TR mice (Bales
et al., 2009). The increased absolute levels of apoE in APOE2 in-
dividualsmight help with preventing Ab accumulation in the brain
and decrease the risk for developing AD. In vitro experiments
have revealed that Ab can bind directly to LDLR (Basak et al.,
2012). Overexpression of LDLR significantly increases cellular
uptake of Ab in astrocytes, whereas deletion of LDLR has the
opposite effect (Basak et al., 2012). Consistent with these
findings, overexpression of LDLR in the brain decreases Ab
deposition in amyloid model mice (Kim et al., 2009); however,
the effects of LDLR deletion on Ab deposition is less clear (Cao
et al., 2006; Fryer et al., 2005a), indicating that although LDLR
is capable of metabolizing Ab in the brain, its pathophysiological
role requires further investigation.
LRP1 is an important apoEmetabolic receptor in the brain and
also among the most studied Ab receptors. In vivo experiments
show that overexpression of a functional LRP1 minireceptor
(mLRP2) in mouse brain significantly decreases apoE levels (Zer-
binatti et al., 2006), whereas neuronal-specific LRP1 deletion
leads to an increase of apoE levels (Liu et al., 2007). LRP1 has
been shown to mediate cellular Ab uptake in neurons (Kanekiyo
et al., 2011), astrocytes (Koistinaho et al., 2004), microglia
(Laporte et al., 2004), vascular smooth muscle cells (Bell et al.,Neuron 81, February 19, 2014 ª2014 Elsevier Inc. 745
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2004; Yamada et al., 2008). The in vivo experiments have shown
that exogenous Ab application through intracerebral microinjec-
tions is rapidly removed from the brain, whereas an LRP1-spe-
cific antibody slows this elimination process (Shibata et al.,
2000). Consistent with these results, conditional knockout of
the Lrp1 gene in mouse forebrain neurons (Kanekiyo et al.,
2013) or vascular smooth muscle cells (Kanekiyo et al., 2012)
exacerbated amyloid pathology in amyloid model mice by sup-
pressing cellular Ab uptake and lysosomal degradation. Ab binds
directly to immobilized LRP1 receptor fragments with high affin-
ity (Deane et al., 2004), although an opposing result was also re-
ported (Yamada et al., 2008). LRP1 also indirectly interacts with
Ab through its ligands, including apoE, a2-macroglobulin (Narita
et al., 1997), and prion proteins (Rushworth et al., 2013). It was
shown that cellular prion protein (PrPc) mediates Ab oligomer
binding to the cell surface (Laure´n et al., 2009; Wang et al.,
2013), where LRP1 functions as a coreceptor of PrPc (Rushworth
et al., 2013). Furthermore, it is important to note that LRP1 and
HSPG can form immunoprecipitable complexes at the cell sur-
face, which might further regulate the metabolism of apoE and
Ab (Wilsie and Orlando, 2003). Our work has shown that Ab ap-
pears to initially bind to cell surface HSPG, followed by endocy-
tosis through either LRP1-independent or -dependent manners
(Kanekiyo et al., 2011). HSPG deficiency significantly decreases
cellular Ab binding and uptake (Kanekiyo et al., 2011). The fact
that several types of HSPG are found to be colocalized with se-
nile plaques and CAA in the brain of AD patients (van Horssen
et al., 2003) further supports the important role HSPG plays in
apoE and Ab cellular metabolism. Interestingly, peripheral treat-
ment with a low-molecular-weight heparin inhibits the binding of
Ab to HSPG and significantly decreases Ab concentration and
deposition in the brain of amyloid model mice (Bergamaschini
et al., 2004). The effects observed with heparin treatment are
different to the phenotype displayedwith LRP1 or LDLR deletion,
where Ab deposition is exacerbated. These observations
suggest that the pathways of cellular Ab and apoE uptake are
differently regulated depending on their binding to specific
apoE receptor LDLR, LRP1, and/or HSPG. Conditional deletion
of HSPG in the brain can help to address the in vivo roles of
this sometimes promiscuous molecule in brain Ab metabolism.
In this regard, it is important to note that HSPG also plays impor-
tant roles in cellular uptake of tau and a-synuclein (Holmes et al.,
2013), a critical step for propagation of disease-related pathol-
ogy (Guo et al., 2013). Thus, further studies to dissect how
HSPG regulates the endocytosis and trafficking of a variety of
pathogenic proteins including Ab, apoE, tau, and a-synuclein
may provide new insights into the pathogenesis of multiple
neurodegenerative diseases.
Several studies have demonstrated that apoE enhances
cellular Ab uptake through its ability to form a complex. Soluble
Ab and recombinant apoE form SDS-stable complexes, which
enhance Ab internalization in primary neurons (Gylys et al.,
2003). Recombinant apoE accelerates neuronal Ab uptake in
an isoform-dependent manner, with apoE3 more efficiently facil-
itating Ab binding to the cell surface than apoE4 (Li et al., 2012).
However, other studies have shown that apoE might compete
with Ab for receptor binding and subsequent cellular uptake.746 Neuron 81, February 19, 2014 ª2014 Elsevier Inc.Recombinant apoE was shown to reduce the uptake of Ab olig-
omers, but not fibrils, in astrocytes (Nielsen et al., 2010). ApoE
particles interfere with the cellular uptake of soluble Ab through
an LRP1-dependent pathway in astrocytes (Verghese et al.,
2013). These seemingly conflicting results may be induced by
specific experimental conditions, including the source and the
amounts of apoE and Ab, the specific cell types tested, and/or
the specific detection methods. Because Ab and heparin are
capable of binding to both the lipid-binding region and the recep-
tor-binding region in apoE (Figure 1) and the complex interacting
network of apoE receptors, apoE might either facilitate or
compete with Ab for cellular binding and uptake depending on
their concentrations, Ab aggregation state, apoE isoform, apoE
lipidation state, and expression pattern of the receptors on the
cell surface (Figure 3). Further studies, in particular those de-
signed in vivo, are necessary to clarify apoE isoform-dependent
functions in cellular Ab uptake and metabolism.
It is clear that the majority of cell-internalized Ab traffics
through the early and late endosomes en route to lysosomes
for degradation (Hu et al., 2009; Li et al., 2012), although a small
portion of cell-internalized Ab does recycle through Rab11-pos-
itive recycling endosomes (Li et al., 2012). Thus, cellular Ab
uptake is in general a beneficial pathway for Ab clearance. How-
ever, when lysosomal degradation is impaired (Li et al., 2012) or
when Ab concentration overwhelms this compartment in AD
brains (Hu et al., 2009; Knauer et al., 1992), trafficking to lyso-
somes can be detrimental as it could lead to Ab aggregation
(Hu et al., 2009), which is highly favorable in the acidic envi-
ronment found in lysosomes (Pera´lvarez-Marı´n et al., 2008)
(Figure 3). Ab aggregates in turn likely induce lysosomal dysfunc-
tion and cellular toxicity. More importantly, these lysosomal-initi-
ated Ab aggregates can further accelerate Ab aggregation,
which could eventually contribute to the genesis of extracellular
Ab oligomers and amyloid plaque deposition. Interestingly, apoE
also aggregates faster under acidic pH conditions found in lyso-
somes with apoE4 aggregating more than apoE3 (Garai et al.,
2011). Thus, the aggregative nature of both Ab and apoE4 in
the acidic lysosomes demonstrates that these AD pathogenic
molecules might coaggregate in the lysosomes as accidental
encounters and/or partners.
ApoE in Ab Clearance: Distinct Roles and Isoform-
Specific Effects
While Ab is continuously generated in the brain, it is efficiently
eliminated under physiological conditions. In human brains, the
Ab clearance rate is calculated to be 8.3% per hour (Bateman
et al., 2006). There are three major pathways by which Ab is
cleared from the brain: (1) through proteolytic degradation, (2)
by cellular clearance through lysosomal degradation in brain pa-
renchyma cells (microglia, astrocytes, neurons), and (3) by cere-
brovascular system-mediated clearance including the interstitial
fluid (ISF) drainage pathway, local cellular clearance, and blood-
brain barrier (BBB) (Figure 4). In vivo experiments have shown
that Ab clearance is slower in apoE4-TR mice compared with
apoE3-TRmice (Castellano et al., 2011). However, the pathways
contributing to apoE-regulated Ab clearance can be complex as
discussed above as the clearance of soluble Ab in brain ISF is
increased in apoE-KO mice (DeMattos et al., 2004).
Figure 4. Major Ab Clearance Pathways and
Effects of apoE Isoforms
Ab is predominantly generated in neurons (1) and
eliminated through threemajor clearance pathways
including proteolytic degradation by (2) endopepti-
dases (e.g., NEP, IDE) (Saido and Leissring, 2012),
(3) cellular clearance by cells in the brain paren-
chyma (neurons, astrocytes, and microglia) (Kane-
kiyo et al., 2013; Koistinaho et al., 2004), and (4) ISF
drainage,where it is degradedby vascular cells (Bell
et al., 2009; Kanekiyo et al., 2012) or transported out
of the brain through the BBB (Ito et al., 2013).
Disturbance of these pathways induces Ab accu-
mulation and deposition in the brain parenchyma as
amyloid plaques (5), in the perivascular region as
CAA (6), and sometimes also inside neurons (7).
ApoE is generated mainly by the glial cells (8) and
encounters Ab in all these pathways. ApoEprobably
facilitates Ab clearance by activating enzymatic
degradation (2) and phagocytosis (3) in an isoform-
dependent manner (apoE3 > apoE4). However,
apoE might also suppress Ab clearance (apoE4 >
apoE3) by either competing with Ab for receptor
bindingor by retaining Ab from its clearance through
the BBB (4). ApoE4 exacerbates Ab deposition
as amyloid plaques and CAA formation when
compared with apoE3 (5 and 6) (Fryer et al., 2005b).
LRP1, LDLR, and HSPG, which are expressed in all
major cellular Ab clearance pathways, regulate Ab
clearance either directly or through apoE.
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(NEP) and insulin-degrading enzyme (IDE) in both intracellular
and extracellular compartments (Figure 4) (Saido and Leissring,
2012). Deletion of NEP or treatment with an NEP inhibitor leads
to increased levels of Ab (Farris et al., 2007; Iwata et al., 2000).
The IDE-KO mice show increased accumulation of endogenous
Ab in the brain (Farris et al., 2003). Consistent with these findings,
overexpression of NEP and/or IDE lowers Ab levels by around
90% and reduces amyloid pathology (Leissring et al., 2003).
Soluble apoE/Ab complexes isolated from human brains were
more susceptible to proteolytic degradation than apoE-free Ab
(Russo et al., 1998). Similarly, NEP-mediated Ab degradation in
microglia is enhanced by exogenous apoE, in an isoform-depen-
dent manner (apoE2 > apoE3 > apoE4). Extracellular Ab degra-
dation by IDE and NEP is also facilitated by apoE. Interestingly,
lipidated apoE shows stronger effects on the capacities of
NEP and IDE to degrade Ab than nonlipidated apoE (Jiang
et al., 2008). Although further studies are needed, it is tempting
to speculate that apoE facilitates Ab degradation by converting
the Ab structure into one that is more recognizable by NEP
and IDE.
Cellular uptake of Ab by astrocytes and microglia is likely to
represent a more functional pathway for Ab clearance (Figure 4).
When brain sections bearing Ab plaques from amyloid model
mice were cultured with adult mouse astrocytes, the astrocytes
internalized and degraded Ab in both an apoE- and LRP1-depen-
dent manner (Koistinaho et al., 2004). In microglia, soluble Ab is
probably internalized by fluid-phase macropinocytosis into lyso-
somes for degradation (Mandrekar et al., 2009), whereas Ab ag-
gregates interact with a multicomponent cell surface receptor
complex and are internalized through phagocytosis (Bamberger
et al., 2003). Microglia and macrophage are known to have two
activation statuses: classically activated (M1) and alternativelyactivated (M2) stages. M1 cells produce proinflammatory
cytokines, which damage neurons, whereas M2 cells trigger
anti-inflammatory/neurotrophic pathways and clear Ab by
phagocytosis in AD (Aguzzi et al., 2013). Microglial activation is
probably modulated by apoE, as apoE has been shown to
convert macrophages from the proinflammatory M1 to the anti-
inflammatory M2 phenotype (Baitsch et al., 2011). ApoE4 is
less effective in anti-inflammatory functions than apoE3 inmicro-
glia (Zhu et al., 2012). Furthermore, apoE isoforms differently
regulatemicrogliamigration in response to activation,withmicro-
glia from apoE4-TR mice exhibiting slower migration than those
from apoE3-TR mice (Cudaback et al., 2011). Thus, apoE pro-
motes Ab clearance by activating phagocytosis and migration
inmicroglia,where apoE4hasa reducedcapacity to induce these
phenotypes than apoE3. Recent genetic studies have also iden-
tified several new AD risk genes that are potentially involved
in regulating neuroinflammation-related functions including
TREM2, CLU, CR1, CD33, and ABCA7 (Guerreiro et al., 2013;
Harold et al., 2009; Hollingworth et al., 2011; Lambert et al.,
2009; Naj et al., 2011). Although the functional relationships
between apoE and proteins encoded by these genes are not
fully understood, thediscovery of thesenewAD risk genes further
implies a critical relationship between neuroinflammation and AD
pathogenesis. As Clu and ABCA7 are also related to lipid meta-
bolism, further studies may demonstrate their cooperative roles
with apoE in Ab clearance.
Neurons also have an ability to eliminate Ab through its uptake
and lysosomal degradation (Figure 4) (Li et al., 2012). It should be
noted that neurons have the highest risk of encountering Ab in
the brain, because Ab is predominantly produced in neurons.
The functional role of neurons in brain Ab clearance is clearly
shown by our recent work demonstrating that when LRP1
is deleted exclusively in neurons in adult mouse brain, theNeuron 81, February 19, 2014 ª2014 Elsevier Inc. 747
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accumulation and pathology (Kanekiyo et al., 2013).
Cerebrovascular systems also play critical roles in Ab clear-
ance (Figure 4). Pathological studies from AD patients show
that Ab deposits in the vascular smooth muscle cell layer of ce-
rebral blood vessels and capillaries in the form of CAA as well as
senile plaques (Rensink et al., 2003; Revesz et al., 2003). ISF
flows along periarterial spaces in the brain and joins the CSF
to drain into the cervical lymph nodes and/or venous blood
flow. Part of ISF can directly enter the arterial blood flow through
the BBB (de Boer andGaillard, 2007;Marques et al., 2013). In the
ISF drainage pathway, Ab is thought to be eliminated through
cellular degradation by vascular cells (smooth muscle cells, peri-
cytes, endothelial cells, and astrocytes), proteolytic degradation,
and clearance through the BBB. Remaining Ab in ISF may be
eventually drained into lymph flow and venous blood flow.
Thus, the disturbance of ISF drainage pathway probably causes
Ab accumulation in the brain. In fact, the water channel aqua-
porin-4 has been shown to be a crucial component in this pro-
cess. Aquaporin-4 null mice exhibit an 70% reduction in ISF
clearance rate and a suppressed clearance of soluble Ab
through reduction of ISF drainage (Iliff et al., 2012), supporting
an importance role of this pathway in Ab clearance. Epide-
miological studies have also shown that practically all
well-described risk factors for AD, including diabetes mellitus,
atherosclerosis, stroke, hypertension, transient ischemic at-
tacks, microvessel pathology, and smoking, have a vascular
component that disturbs cerebral vascular functions (de la Torre,
2002). Pathological evidence indicates that LRP1 levels are
significantly decreased during aging and AD, in particular in
the brain vasculature (Bell et al., 2009; Deane et al., 2004).
LRP1 in vascular smooth muscle cells regulates Ab clearance
in the ISF drainage pathway. Deletion of LRP1 in vascular mural
cells enhances Ab deposition both in brain parenchyma as amy-
loid plaques and in vasculature as CAA (Kanekiyo et al., 2012).
BBB efflux of Ab also represents a major pathway for brain Ab
clearance. The overall clearance rate constant of Ab40 in mouse
cerebral cortex is 3.21 3 102/min, while the elimination rate for
brain-blood clearance is 1.483 102/min (Ito et al., 2013). Due to
technical limitations, it is difficult to precisely distinguish Ab
clearance through the BBB and simultaneous clearance through
other pathways. Current research implicates apoE and apoE re-
ceptors as major regulators in Ab clearance through the BBB.
One such study demonstrates that Ab is cleared rapidly across
the BBB through LRP1, where apoE significantly disturbs this
process (Bell et al., 2007). ApoE2/Ab and apoE3/Ab complexes
are cleared at the BBB via LRP1 and VLDLR at a substantially
faster rate than apoE4/Ab complexes (Figure 4) (Deane et al.,
2008). In addition, LDLR has also been shown to mediate
brain-blood Ab clearance (Castellano et al., 2012). Moreover,
apoE4, but not apoE2 or apoE3, leads to the breakdown of the
BBB (Bell et al., 2012; Nishitsuji et al., 2011), which causes a
reduction in cerebral blood flow (Bell et al., 2012). This harmful
effect of apoE4 on BBB integrity might further compromise Ab
clearance. Consistent with these findings, APOE4 carriers have
more severe CAA pathology, in particular capillary CAA when
compared with APOE4 noncarriers (Richard et al., 2010; Thal
et al., 2002). Taken together, apoE and apoE receptors are748 Neuron 81, February 19, 2014 ª2014 Elsevier Inc.clearly involved in Ab clearance through the cerebrovascular
systems, probably in ways depending on the presence of spe-
cific apoE isoforms and apoE receptors. Future studies should
focus on addressing whether apoE isoforms produced in brain
parenchyma differ from those by vascular cells in regulating
brain Ab clearance and how apoE receptors expressed in spe-
cific vascular cell types regulate these events.
ApoE-Targeted Therapy for AD: The Dilemma when
Modulating apoE
Because of the importance of apoE in AD pathogenesis, several
therapeutic strategies that target apoE for AD have been
proposed. Among them, retinoid X receptor (RXR) and liver X
receptor (LXR) agonists are promising candidates. RXR forms
heterodimers with LXR, peroxisome proliferator-activated re-
ceptor g (PPARg), or retinoic acid receptor (RAR) to regulate
gene networks that control multiplemetabolic systems. In partic-
ular, these nuclear receptors are known to control the transcrip-
tion of ABCA1 and apoE (Pe´rez et al., 2012). Oral administration
of an RXR agonist, Bexarotene, suppressed Ab deposition and
improved cognitive function in an apoE-dependent manner in
amyloid model mice (Cramer et al., 2012), although these results
are likely somewhat disputed by several follow-up studies. The
LXR agonist TO901317 is also shown to increase apoE levels
in the brain, facilitate Ab clearance, and reverse the memory
deficit in amyloid model mice (Riddell et al., 2007; Terwel et al.,
2011). Thus, treatments that result in increased levels of apoE
in the brain are probably beneficial in AD therapy. However,
this notion has to be carefully dissected as apoE4 clearly has
harmful effects (Bu, 2009). Under stress conditions, neuronally
expressed apoE often becomes fragmented, which damages
mitochondria and cytoskeleton (Huang and Mucke, 2012). In
addition, in vitro experiments have shown that apoE4 facilitates
Ab production by promoting amyloidogenic processing of APP
as a functional consequence of its interaction with APP (Vincent
and Smith, 2001). Thus, it might be particularly detrimental to
upregulate apoE4 production in AD. Rather than focusing on
increasing apoE, it has been proposed that increasing apoE lip-
idationmight be the key for apoE-based therapy. ApoE lipidation
is mediated by ABCA1 (Koldamova et al., 2010). Importantly,
deletion of ABCA1 increases Ab deposition in amyloid model
mice (Wahrle et al., 2005), whereas its overexpression sup-
presses Ab deposition (Wahrle et al., 2008). Furthermore, the
haploinsufficiency of ABCA1 significantly decreases Ab clear-
ance in apoE4-TR mice, but not in apoE3-TR mice (Fitz et al.,
2012), suggesting that the less efficient lipid transport phenotype
associated with apoE4 might allow for greater manipulation at
the level of apoE lipidation.
The argument to decrease apoE expression to treat AD is
championed by the fact that apoE is essential for Ab deposition
as discussed above. Recent studies have also shown that
decreased apoE expression under haploinsufficiency of human
apoE also results in less Ab deposition in amyloidmousemodels,
which is independent of apoE isoforms (Bien-Ly et al., 2012; Kim
et al., 2011). Further, immunotherapy for apoE also reduces Ab
accumulation. When amyloid model mice were intraperitone-
ally administered with anti-mouse apoE-specific antibody for
14 weeks, amyloid deposition was dramatically reduced by
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(Kim et al., 2012). These results suggest that decreasing apoE
levels has beneficial effects and that anti-apoE immunization
can be explored as a novel therapeutic tool, at least from the
perspective of Ab deposition. However, further studies are
needed to determine how decreased apoE levels affect Ab
oligomerization, neurotoxicity, synaptic integrity, and cognitive
function. It is also an undisputed fact that apoE mediates
cholesterol homeostasis, particularly in the brain; thus, these ap-
proaches to solely decrease apoE levels over extended periods
of time may induce harmful, perhaps unforeseen, side effects.
The interaction between apoE and Ab can also be targeted for
therapy, although the outcome is less clear. Despite evidence
supporting a beneficial role of apoE/Ab complexes, the presence
of these proteins in an environment that favors Ab aggregation,
such as lysosomes and amyloid plaques, could be harmful.
Supporting this, a synthetic peptide mimicking the apoE-binding
sequence of Ab, Ab12-28P, reduces Ab deposition and amelio-
rates memory deficits in amyloid model mice (Sadowski et al.,
2004). Other methods that target apoE for therapy include
apoE4 structural correctors (Chen et al., 2012) and increasing
the functions of apoE receptors (Shinohara et al., 2010).
Taken together, the choice of increasing or decreasing apoE is
an unavoidable dilemma in our efforts to develop apoE-based
AD therapies. Despite this dilemma, apoE remains a promising
target. Both pharmacological manipulations of apoE expression
and lipidation and potentially new genetic mouse models that
allow for testing the effects of increasing or reducing apoE
should help to clarify our path to new AD therapy.
Summary and Perspective
APOE4 is the strongest genetic risk factor for late-onset AD.
ApoE4 appears to drive amyloid pathology in humans and in an-
imal models; however, it is clear that apoE4 also contributes to
AD pathogenesis in a manner that is independent of Ab. ApoE
and Ab interact with each other and share common receptors
including LRP1, LDLR, and HSPG. Importantly, the interactions
among apoE, Ab, and their receptors probably vary depending
on their concentrations, the apoE isoform involved, lipidation
status, Ab aggregation status, and receptor distribution patterns.
Thus, apoE isoforms probably have different, sometimes seem-
ingly conflicting, roles in Ab aggregation and clearance. First,
apoE reduces Ab oligomerization and fibril formation but is
also essential for amyloid deposition. Second, apoE competes
with Ab for their receptor binding but can also facilitate cellular
Ab uptake by forming apoE/Ab complexes. Third, apoE facili-
tates the enzymatic degradation and phagocytosis of Ab by glial
cells, but apoE compromises Ab elimination through the BBB. As
a result, it has been difficult to elucidate the exact pathological
mechanism by which apoE regulates Ab clearance. Nonethe-
less, it is clear that multiple pathways are involved and apoE
and Ab appear to share several properties, suggesting that their
interaction goes beyond accidental encounters. In fact, apoE-
targeted therapy aimed at ameliorating amyloid pathology and
improving cognitive function via RXR/LXR agonists or increasing
apoE lipidation hold promise and warrant further investigation.
In summary, apoE has multiple functions in regulating Ab
clearance, Ab aggregation, and Ab-independent pathways inAD pathogenesis. A critical challenge is to determine whether
increasing or decreasing apoE, or simply its lipidation, is benefi-
cial, and how the presence of apoE4 affects the outcomes.
Future studies should also be focused on addressing why a sin-
gle amino acid change from apoE3 to apoE4 causes profound
differences in their properties and functions and how we can uti-
lize our knowledge to design new therapies for AD targeting
apoE pathway.
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